·May 25, 2022
Respiratory tract infection
Even before the Covid-19 pandemic, RTIs were a leading cause of hospitalization in children, many of whom may go on to develop chronic conditions such as asthma.
Download PDFA case study to learn more about the challenge of running clinical studies during pandemic lockdowns
OM Pharma wanted to assess the feasibility of running clinical trials of a treatment to prevent respiratory tract infections (RTIs) during the Covid-19 lockdown.
Nova built a multi-scale in silico model capturing how non-pharmaceutical interventions (NPI) - such as lockdown or mask-wearing - affect rates of infection with the most common respiratory viruses, and the impact of the prophylactic treatment OM-85 under different NPI scenarios in the context of an upcoming trial.